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Chronic Apocynin Treatment Attenuates Beta Amyloid
Plaque Size and Microglial Number in hAPP(751)SL Mice
Melinda E. Lull, Shannon Levesque, Michael J. Surace, Michelle L. Block*
Department of Anatomy and Neurobiology, Virginia Commonwealth University Medical Campus, Richmond, Virginia, United States of America
Abstract
Background: NADPH oxidase is implicated in neurotoxic microglial activation and the progressive nature of Alzheimer’s
Disease (AD). Here, we test the ability of two NADPH oxidase inhibitors, apocynin and dextromethorphan (DM), to reduce
learning deficits and neuropathology in transgenic mice overexpressing human amyloid precursor protein with the Swedish
and London mutations (hAPP(751)SL).
Methods: Four month old hAPP(751)SL mice were treated daily with saline, 15 mg/kg DM, 7.5 mg/kg DM, or 10 mg/kg
apocynin by gavage for four months.
Results: Only hAPP(751)SL mice treated with apocynin showed reduced plaque size and a reduction in the number of
cortical microglia, when compared to the saline treated group. Analysis of whole brain homogenates from all treatments
tested (saline, DM, and apocynin) demonstrated low levels of TNFa, protein nitration, lipid peroxidation, and NADPH oxidase
activation, indicating a low level of neuroinflammation and oxidative stress in hAPP(751)SL mice at 8 months of age that was
not significantly affected by any drug treatment. Despite in vitro analyses demonstrating that apocynin and DM ameliorate
Ab-induced extracellular superoxide production and neurotoxicity, both DM and apocynin failed to significantly affect
learning and memory tasks or synaptic density in hAPP(751)SL mice. To discern how apocynin was affecting plaque levels
(plaque load) and microglial number in vivo, in vitro analysis of microglia was performed, revealing no apocynin effects on
beta-amyloid (Ab) phagocytosis, microglial proliferation, or microglial survival.
Conclusions: Together, this study suggests that while hAPP(751)SL mice show increases in microglial number and plaque
load, they fail to exhibit elevated markers of neuroinflammation consistent with AD at 8 months of age, which may be a
limitation of this animal model. Despite absence of clear neuroinflammation, apocynin was still able to reduce both plaque
size and microglial number, suggesting that apocynin may have additional therapeutic effects independent of anti-
inflammatory characteristics.
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Introduction
Alzheimer’s disease (AD) is a devastating and progressive neuro-
degenerative disease that culminates in dementia, affecting over 5
million people in the United States alone. Current treatment is largely
unable to halt disease progression. The hallmark neuropathology of
AD consists of insoluble extracellular plaques containing b -amyloid
(Ab) and intraneuronal neurofibrillary tangles in the cortical region of
the brain.Microglia, the resident immune cells in the brain, have been
implicated in the progressive nature of numerous neurodegenerative
diseases, particularly AD [1]. However, traditional anti-inflammatory
therapies such as Non-steroidal Anti-inflammatory Drugs (NSAIDs)
have produced conflicting results [2], highlighting the need for new
and more specific anti-inflammatory targets. Here, we propose that
targeting NADPH oxidase and neurotoxic microglial activation may
be of significant therapeutic relevance for AD.
NADPH oxidase is an enzyme complex in phagocytes, such as
microglia, that is activated during host defense to catalyze the
production of superoxide from oxygen [3]. A variety of stimuli,
including bacteria components [4], inflammatory peptides [3], Ab
[5], and multiple other neurotoxins [6] activate microglial
NADPH oxidase, causing the production of neurotoxic reactive
oxygen species (ROS). In fact, NADPH oxidase is activated in the
brains of AD patients [7] and the catalytic subunit (gp91) is
upregulated in Parkinson’s disease (PD) [8], further implicating the
enzyme complex in neurodegenerative diseases.
The premise of deleterious microglial activation in AD has been
supported by analysis of post-mortem brains from AD patients
[9,10], where microglial activation occurred before neuropil
damage in the disease process [11], suggesting a causal role. The
Amyloid Hypothesis holds that Ab has a causative role in AD
pathology, which may occur through direct toxicity to neurons
[12,13] and microglia-mediated neurotoxicity [14,15]. In fact,
evidence shows that microglia cluster around senile plaques and
neurofibrillary tangles [10,16], become activated [17], and
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produce neurotoxic factors, including nitric oxide (NO) [18],
superoxide [15,19], and tumor necrosis factor alpha (TNFa) [20].
Several studies have demonstrated that Ab will both recruit and
activate microglia [16,17], further supporting a role for both Ab
and microglia in AD progression [21]. Interestingly, the receptor
complex necessary for microglia to recognize and phagocytize Ab
fibrils are also the same receptors responsible for Ab activation of
microglial NADPH oxidase and the production of superoxide
[22,23], indicating microglia themselves are a source of oxidative
stress [23]. Furthermore, microglial NADPH oxidase has also
been implicated as a critical component to neurotoxic reactive
microgliosis [24,25,26]. Reactive microgliosis refers to the toxic
microglial response to neuronal damage responsible for a chronic
cycle of neuroinflammation and neurotoxicity [27], a process
believed to underlie diverse neurodegenerative diseases [24,25,26].
Several compounds have demonstrated the ability to inhibit
microglial NADPH oxidase, including memantine [28,29], statins
[30], ibuprophin [5], dextromethorphan (DM) [31,32,33], and 49-
Hydroxy-39-methoxyacetophenone (apocynin) [34]. DM is a
noncompetitive N-methyl-d aspartate (NMDA) receptor agonist
that has been shown to have both anti-inflammatory [31] and
neuroprotective properties in models of Parkinson’s disease
[31,32,33], independent of the NMDA receptor and through
inhibition of microglial NADPH oxidase [35,36]. Apocynin was
originally isolated from the medicinal plant Picrorhiza kurroa, has
low toxicity, impairs the assembly of the NADPH oxidase complex
[37], and is neuroprotective against microglia-mediated neurotox-
icity in PD models [38]. While clearly successful in PD models
[31,32,33], until now the ability of DM and apocynin to offer in
vivo neuroprotection in AD models was unknown.
In the current study, we addressed whether chronic adminis-
tration of known NADPH oxidase inhibitors (apocynin and DM),
beginning at the time plaque deposition began to occur in
hAPP(751)SL mice, could prevent neuroinflammation, neuron
damage, and behavioral learning and memory deficits.
Materials and Methods
Reagents
Lipopolysaccharide (LPS; strain O111:B4) was purchased from
EMD Chemicals (Gibbstown, NJ). Cell culture reagents were
obtained from Invitrogen (Carlsbad, CA). HALT protease inhibitor
was obtained from Thermo Fisher Scientific (Rockford, IL).
Fluorescent Ab peptide was purchased from AnaSpec, Inc.
(Fremont, CA), and non-fluorescent Ab was purchased from
American Peptide Company (Sunnyvale, CA). Dextromethorphan,
apocynin, staurosporine, fMetLeuPhe and all other reagents were
purchased from Sigma Aldrich Chemical Co. (St. Louis, MO).
Animals
A total of 53 male transgenic hAPP(751)SL mice with a C57BL/
6xCBA background were used for the in vivo portion of this study.
The hAPP(751)SL mice over-express human APP(751) with the
London (V717I) and the Swedish (K670M/N671L) mutations
under the regulatory control of the murine-Thy-1 promoter, which
ensures high expression in brain neurons, with little expression in
the periphery. Due to the London mutation, high levels of b-
amyloid 1–42 are expressed all over the brain, particularly in the
cortex and hippocampus. The hAPP(751)SL mice develop plaques
consisting of amyloid depositions starting at 3 to 4 months, where
deposits begin to accumulate in the hippocampus by 7 months.
The hAPP(751)SL mice also show neuronal damage with
increasing age, particularly at 14 months [39]. The hAPP(751)SL
mice fail to show motor deficits, but present profound deficits for
tests of cognition, including the Morris Water Maze and object
recognition tests [40]. The hAPP(751)SL mice were purchased
from, housed at, and treatment procedures were completed at
JSW Life Sciences (Grambach, Austria).
For in vitro studies with primary microglial cultures, timed-
pregnant Fisher 344 rats were purchased from Charles River
Laboratories (Raleigh, NC). All animals were housed under a
constant 12 hour light and dark cycle, and food and water were
available ad libitum. All experiments were approved by the Virginia
Commonwealth University Animal Care and Use Committee
(AM10124) and conducted in strict accordance with guidelines set
forth by the National Institutes of Health.
Animal studies-treatment
The hAPP(751)SL mice were randomly assigned to one of 4
treatment groups: vehicle, dextromethorphan (DM) 15 mg/kg,
DM 7.5 mg/kg, or apocynin 10 mg/kg. Starting at 4 months of
age (62 weeks), animals were either treated with saline (vehicle,
n = 14), DM 15 mg/kg (n= 13), DM 7.5 mg/kg (n= 12), or
apocynin 10 mg (n = 14) by oral gavage daily for 4 months.
Morris Water Maze (MWM)
At the end of the 4 month treatment period, mice were trained
in the MWM. The MWM tests took place in a black circular pool
with a diameter of 100 cm filled with water and divided into four
virtual quadrants. A transparent platform (diameter of 8 cm)
was placed in the southwest quadrant of the pool. The walls
surrounding the pool were marked with bold geometric symbols
for spatial orientation. During behavioral testing, mice were
placed in the pool and allowed to find the hidden platform. If
the mouse was unable to locate the platform, the investigator
guided the mouse. After each trial, mice were allowed to rest on
the platform for 10–15 seconds and orient themselves. Mice
performed three swimming trials per day for four consecutive days.
During the trials, motion within the pool was detected with a
computerized tracking system. These data were used to quantify
swimming speed, escape latency (time, in seconds, for the mouse to
find the hidden platform and escape the water), pathway (length
traveled, in meters, before reaching the target), and abidance in
the target quadrant (measured in percentage of the total trial time).
Following the final trial on the fourth day, mice completed a
‘probe trial’ where the platform was removed and the number of
crossings over the former platform position and abidance in the
target quadrant were measured.
Tissue collection
Following behavioral testing, animals were sacrificed and brain
tissue was collected for further study. All mice were sedated using
Isofluran inhalation before tissue collection. Mice were transcar-
dially perfused with 0.9% saline and the brains were removed and
divided into the right and left hemisphere. The left hemisphere
was immediately processed for histology, while the right
hemisphere was frozen on dry ice and stored at 280uC until use.
TBARS assay
Lipid peroxidation in tissue samples was determined by the
thiobarbituric acid reactive substances (TBARS) assay. Brain tissue
was homogenized in 2.5% SDS with 5 mM butylated hydro-
xytoluene. 400 mL of this homogenate was mixed with 375 mL of
20% acetic acid, pH 3.5, and 225 mL of thiobarbituric acid
(1.33%). The resulting mixture was incubated for 1 hour at 95uC.
After incubation, 1 mL of 15:1 butanol:pyridine was added and
the mixture was centrifuged for 10 minutes at 4000 g. The amount
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of TBARS were determined by measuring the optical density of
the organic layer at 535 nm and comparing the absorbance to a
malondialdehyde (MDA) standard.
Cellular fractionation: membrane preparation
Membrane fractions from both cell culture and tissue were
isolated using differential centrifugation followed by lipid
extraction [41]. Frozen brain tissue was suspended in fraction-
ation buffer (FB; 20 mM HEPES, 250 mM sucrose, 1 mM
EDTA, 10 ul/mL HALT protease inhibitor, 10 mM DTT,
pH 7.5) and incubated for one minute at 37uC [42]. Brain
samples were homogenized with a Teflon pestle 15 times and the
resulting solution was centrifuged at 4uC, 600 g for 10 minutes.
Supernatant was removed and an additional 2.5 mL of FB was
added to the pellet. After resuspending the pellet, the samples
were spun again at 4uC, 600 g for 10 minutes. The resulting
supernatant was added to the first and centrifuged at 4uC,
15,000 g for 10 minutes. The supernatant from this spin was
then centrifuged at 4uC, 100,000 g for 1 hour. The resulting
pellet was solublized in 150 uL of 50 mM ammonium bicar-
bonate by vortexing. To this solution, 1 mL of 2:1 TFE:Chloro-
form (freshly prepared) was added. Samples were placed on ice
and vortexed for 1 minute every 10 minutes and then
centrifuged at 4uC, 16,000 g for 10 minutes. The bottom
chloroform layer (containing lipids) was removed, and the
remaining top layer and insoluble phase were evaporated at
37uC in a SpeedVac. The resulting pellet was suspended in
solublization buffer (SB; 8 M Urea, 25 mM TrisHCl, 2% SDS,
10 mM DTT, pH 7.5) and protein concentration was deter-
mined using the Coomassie Plus (Bradford) Protein Assay
(ThermoScientific; Rockford, IL). The resulting samples were
used to determine levels of NADPH oxidase activation by
western blot, measuring the amount of p67 that had translocated
to the membrane.
Protein isolation: whole brain homogenate
From tissue samples, protein was isolated by suspending frozen
tissue in 10 volumes of lysis buffer (Cytobuster Protein Extraction
Reagent; EMD Chemicals; Darmstadt, Germany) with 10 mL/mL
HALT protease inhibitor and 10 mL/mL EDTA. Samples were
homogenized using a motorized pellet mixer and then centrifuged
for 5 minutes at 5000 g. The protein concentration of the resulting
supernatant was determined using a BCA protein assay (Thermo-
Scientific; Rockford, IL).
Immunoblotting
Protein samples were resolved by SDS-PAGE on 10% gels. Protein
was then transferred to nitrocellulose membranes, blocked for 1 hour
in 5% milk, and incubated overnight at 4uC in primary antibody
(mouse anti-GAPDH, rabbit anti-p47-phox, or rabbit anti-p67-phox;
Millipore; Temecula, CA). Blots were then probed with horseradish
peroxidase-conjugated secondary antibodies and visualized using
enhanced chemiluminescence (GE Healthcare; Piscataway, NJ).
TNF a ELISA
The production and release of TNFa was measured using
100 mg/well of whole brain homogenate with a commercial
enzyme-linked immunosorbent assay (ELISA) kit from R&D
Systems (Minneapolis, MN), as described previously [43].
Nitrotyrosine ELISA
The amount of nitrated proteins was measured using 100 mg/
well of whole brain homogenate with a commercial enzyme-linked
immunosorbent assay (ELISA) kit from Millipore (Temecula, CA),
per the manufacturer protocol.
Histology
Tissue fixation and sectioning. One hemisphere from each
mouse brain was fixed by immersion in a solution of 4%
paraformaldehyde in PBS (pH 7.4; freshly prepared) at 4uC for
24 hours. After fixation, brains were transferred to a 15% sucrose/
PBS solution for 24 hours. Brains were then frozen in dry-ice
cooled Isopentane and stored at 280uC until use. Frozen brains
were sectioned into 15-10 mm thick sections per level (5 levels)
starting at the level of the total appearance of the dentate gyrus
and according to Paxinos and Franklin [44].
6E10 and ThioflavinS double staining. The presence of
amyloid depositions was visualized immunohistochemically using
an anti-b-amyloid antibody directed against amino acids 1–17 of
the human b-amyloid peptide (Signet Laboratories; Dedham, MA)
with a Cy3 secondary antibody (Jackson Laboratories; Bar
Harbor, ME). Additionally, tissue sections were stained with
ThioflavinS to recognize beta-sheet structures. Briefly, sections
were washed in H2O for 3 minutes and then placed in 1%
ThioflavinS for 7 minutes. Sections were then washed in 80%
ethanol and PBS before incubating in 1% hydrogen peroxide in
methanol at room temperature for 15 minutes. Sections were then
blocked using MOM-blocking reagent and MOM-diluent
according to the manufacturer’s protocol (MOM-Kit; Vector
Labs; Burlingame, CA). After blocking, samples were incubated
with 6E10 antibody (Signet Laboratories; Dedham, MA) for 30
minutes at room temperature, washed with PBS, and incubated in
10% non-immune goat normal serum for 60 minutes at room
temperature. Sections were then washed and incubated with Cy3
goat anti-mouse antibody (Jackson Laboratories; Bar Harbor, ME)
for 60 minutes in the dark at room temperature. Finally, the
sections were washed in PBS and H2O before adding coverslips.
Measurement of amyloid deposition and plaque load.
Measurement of 6E10 and ThioflavinS staining was done using
Image-Pro Plus software (MediaCybernetics). Briefly, an area
of interest (AOI) was measured encompassing both the hippo-
campus and cortex of each section. Within this AOI, stained
objects were detected that were over a threshold level of in-
tensity and a size of 8.75 mm2. A measurement of the area of
each object, sum of stained area, and the number of objects was
made in each AOI. Mean plaque size was calculated by dividing
the sum area of plaques by the total number of plaques. The
plaque area percentage was measured by dividing the sum area
of plaques by the region area and multiplying the result by 100.
CD11b and synaptophysin immunohistochemistry. To
determine microglial activation in brain slices, slices were stained
with CD11b antibody. Synaptic density was visualized by staining
with a synaptophysin antibody in separate brain slices. For both
antibodies, frozen brain sections were washed for 10 minutes in
PBS and then for 4 minutes in 1 mg/ml sodium-borohydrate in
PBS. Sections were then washed and treated with 1% hydrogen
peroxide in methanol at room temperature for 10 minutes. Non-
specific binding was then blocked with 10% horse serum for 30
minutes and MOM-diluent (Mom-Kit; Vector Labs; Burlingame,
CA) for 5 minutes. Sections were then incubated with anti-CD11b
antibody (Serotec; Raleigh, NC) or anti-synaptophysin antibody
(Thermo Fisher Scientific; Fremont, CA) for 1 hour at room
temperature. Samples were incubated with blocking reagent (10%
non-immuno goat-normal serum for CD11b and Vectastain Elite
ABC Kit (Vector Labs; Burlingame, CA) for synaptophysin) for 20
minutes and room temperature and then washed with PBS.
CD11b samples were then incubated with Cy 3 goat anti-rat
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antibody (Jackson Laboratories; Bar Harbor, ME), washed, and
then stained with DAPI and methanol (Sigma Aldrich Chemical
Co.; St. Louis, MO) for 15 minutes to stain cell nuclei. Sections
were washed in 80% ethanol followed by H2O before adding
coverslips. After primary antibody and blocking of synaptophysin-
stained samples, samples were washed with PBS and incubated for
30 minutes with Vectastain ABC Reagent (Vector Labs;
Burlingame, CA), washed, and developed for 18 minutes with
HistoGreen (Linaris; Bettingen, Germany). Tissues were then
washed in TBS and H2O and dehydrated with a graded alcohol
series and xylol before adding coverslips.
Measurement of microglia number in vivo
The number of microglia in each section was measured
similarly to the protocol for 6E10 and ThioflavinS staining, except
that the count only concentrated on CD11b staining that co-
stained with the nucleus of the cell. Sections were co-stained with
CD11b and DAPI, and cells were only counted in the AOI if their
nucleus was within the name 10 mm thick section.
Measurement of synaptic density in vivo
Synaptic density was also measured using Image-Pro Plus
software (MediaCybernetics). Synapse number was counted at
1000-fold magnification from three images per region (CA1, CA3,
and GDmb regions of the hippocampus). The total number of
synapses was divided by the measured area (mm2) and averaged
between the three images analyzed for each region.
Cortical neuron-glia cultures
Rat cortical neuron-glia cultures were prepared using a
previously described protocol [15]. Briefly, midbrain tissues were
dissected from day 16/17 Fisher 344 rat embryos. Cells were
dissociated via gentle mechanical trituration in minimum essential
medium (MEM) and immediately seeded (56105/well) in poly D-
lysine (20 mg/ml) pre-coated 24-well plates. Cells were seeded in
maintenance media and exposed to the treatment media, as
described previously [15]. Three days after seeding, the cells were
replenished with 500 mL of fresh maintenance media. Cultures
were treated 7 days after seeding.
Microglia-enriched cultures
Primary enriched microglia cultures were prepared from the
whole brains of day-old Fisher 344 rat pups, using the procedure
described previously [45]. Briefly, after removing meninges and
blood vessels, the brain tissue was gently triturated and seeded
(56107) in 175 cm3 flasks. One week after seeding, the media was
replaced. Two weeks after seeding, when the cells had reached a
confluent monolayer of glial cells, microglia were shaken off and
re-plated at 16105 in a 96-well plate. Cells were treated 24 hr after
seeding the enriched microglia. Immunocytochemistry revealed
less than 1% astrocyte or neuron contamination.
Cell lines
The rat microglia HAPI cells were a generous gift from Dr
James R. Connor [46] and were maintained at 37uC in DMEM
supplemented with 10% FBS, 50 U/mL penicillin and 50 mg/mL
streptomycin in a humidified incubator with 5% CO2/95% air.
Beta-amyloid phagocytosis assay
The ability of cells to phagocytose b-amyloid peptide was
measured using a protocol modified from Floden and Combs [47].
Fluorescently labeled b-amyloid 1–42 was prepared by adding
50 mL of 1% sterile ammonium hydroxide to lyophilized peptide,
vortexing, adding 450 mL PBS, and incubating at 37uC for 1 week.
Non-labeled b-amyloid 1–42 was suspended in PBS to give a
1 mM concentration, vortexed, and incubated at 37uC for one
week. Aggregated b-amyloid (fluorescent or non-labeled) was
aliquoted and stored at 220uC until use. To measure phagocy-
tosis, primary microglia were seeded in a 96-well plate (0.56105
cells per well). 24 hours after seeding, cells were treated with
100 mM apocynin (solublized in DMSO) or control media for 30
minutes. Following pretreatment, cells were treated with control
media, 100 mM apocynin, 2 mM non-labeled, aggregated b-
amyloid 1–42, or apocynin and b-amyloid for 24 hours at 37uC.
After 24 hours, media and treatments were removed, and cells
were treated with control media, 100 mM apocynin, or cytocha-
lasin D (control) for 30 minutes. To this treatment was then added
100 uL of 0.1 mM aggregated fluorescent b-amyloid. Plates were
incubated for 6 hours to allow for phagocytosis of the fluorescent
peptide, and then plates were read at 480 nm excitation, 520 nm
emission.
Superoxide Assay
Extracellular superoxide (O2
2) production from microglia was
determined as reported previously [48] by measuring the
superoxide dismutase (SOD) inhibitable reduction of 2-(4-lodophe-
nyl)-3-(4-nitrophenyl)-5-(2,4,-disulfophenyl)-2H-tetrazolium, mono-
sodium salt (WST-1) [49,50,51]. The amount of SOD-inhibitable
superoxide was calculated and expressed as percent of vehicle-
treated control cultures.
Hydrogen peroxide assay
Levels of hydrogen peroxide production in cell culture were
determined as previously described, with slight modifications [52].
Briefly, cells were seeded in a 96-well plate (0.756105 cells per
well) and incubated for 24 hours at 37uC. Cells were then washed
once with warm HBSS, and then 50 mL of HBSS was added to
each well, followed by 50 mL of control (HBSS) or treatment. To
each well, 100 mL of assay mix (200 mM homovanillic acid, 10 U/
mL horseradish peroxidase, 2 mM HEPES, pH 7.5) with or
without catalase (10,000 U/mL), was added. Cells were incubated
for 3 hours at 37uC. Following incubation, 16 mL of stop solution
(0.1 M glycine, pH 10) was added to each well, and the plates
were read at 321 nm excitation, 421 nm emission. Results are
calculated as catalase-inhibitable florescence and reported as a
percent of control values.
Cell survival (MTT) assay
Cell survival was measured using thiazole blue (MTT) to
evaluate metabolic viability of cells [53]. Microglia enriched
cultures (16105 cells per well in a 96-well plate) were pretreated
with 100 mM apocynin or control media for 30 minutes, and then
treated with 100 ng/mL LPS, 2 mM staurosporine, 2 mM Ab,
DMSO, or control media for 24 hours. After the 24 hour
incubation, 5 mg/mL MTT was added to cells in a 96-well plate
for a final concentration of 0.1 mg/mL. Cells were then incubated
for 90 minutes at 37uC. MTT and culture media were removed
from the wells and 100 mL of DMSO was added to each well. The
plate was then placed on an orbital shaker for 30 minutes and the
absorbance was read at 550 nm.
Microglia Cell Number in vitro
Microglial cell number was measured by taking microglia cell
counts from mixed neuron-glia cultures treated for 24 hours with
10 ng/mL LPS or 2 mMAbwith or without 100 mMapocynin. After
treatment, cells were fixed in 3.7% formaldehyde, washed once with
Apocynin, Ab Plaques, & Microglia
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PBS, and treated with 1% hydrogen peroxide. Cells were then
washed three times with PBS and blocked for one hour in PBS with
1% bovine serum albumin, 0.4% Triton X-100 and 4% goat serum.
Plates were then incubated overnight at 4uC in a 1:1000 dilution of
anti-IBA-1 antibody (Wako Pure Chemical Industries, Ltd., Rich-
mond, VA) in Dako antibody diluent (DAKO, Capinteria, CA). After
incubation with primary antibody, cells were washed three times and
incubated with Vectastain ABC Kit reagents according to the
manufacturer’s instructions (Vector Laboratories, Burlingame, CA).
Images were taken on an AxioCamMRc5 imaging system (Carl Zeiss
MicroImaging, Thornwood, NY). Cell numbers were quantified by
counting nine representative areas per well in a 24 well plate at 100X
magnification (an average of numbers counted by at least 2
individuals is reported).
Statistical Analysis
Group differences in the behavioral tests were calculated using a
parametric ANOVA with a Bonferroni’s multiple comparison
post-hoc test or a non-parametric Kruskal Wallis ANOVA with a
Dunn’s multiple comparison test if Gaussian distribution was
missing. For assessments of learning deficits, a two-way ANOVA
was used followed by Bonferroni’s multiple comparison test. For in
vitro studies, significance was calculated using a one-way ANOVA
followed by a Bonferroni post-hoc test. The treatment groups are
expressed as the mean 6 SEM. A value of p,0.05 was considered
statistically significant.
Results
Apocynin reduces plaque size in the cortex and
hippocampus of hAPP(751)SL mice
Brain slices from each group (vehicle, 15 mg/kg DM, 7.5 mg/kg
DM, 10 mg/kg apocynin) were stained for two markers of Ab
deposition: 6E10 (measuring all Ab peptide) and thioflavin S
(measuring b-sheets of Ab). This allowed for the measurement of
plaque number, mean plaque size, and the percentage of area
occupied by plaques in both the cortex and hippocampus. Using
6E10 staining, both the cortex and hippocampus display reduced
plaque size in apocynin treated animals, compared to vehicle-treated
controls (p,0.05; Figure 1). DM, at either dose, did not produce any
significant reduction in plaque size. No significant differences were
observed in plaque number or percentage area in the hippocampus
Figure 1. Apocynin reduces plaque size in the cortex and hippocampus of hAPP(751)SL mice. Mice were treated daily with 15 mg/kg
dextromethorphan (DM), 7.5 mg/kg DM, or 10 mg/kg apocynin for four months. The size of b-amyloid plaques was measured for each group and
compared to control, vehicle-treated animals. Representative images show 6E10 staining of b-amyloid protein for each group in the cortex (A) and
hippocampus (B), respectively. Quantification of plaque size the cortex (C) and hippocampus (D) revealed that only apocynin significantly decreased
the size of plaques, compared to vehicle. DM, at either dose, did not alter plaque size in the cortex or the hippocampus. Plaque size was determined
as the absolute plaque area divided by the absolute plaque number. *p,0.05 vs. vehicle, 1-way ANOVA with Bonferroni post-hoc test.
doi:10.1371/journal.pone.0020153.g001
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or cortex with any of the treatments (data not shown). Additionally,
ThioflavinS staining of b-sheets revealed no differences between
vehicle, DM, and apocynin-treated hAPP(751)SL mice (data not
shown).
Apocynin reduces the number of microglia in the cortex
of hAPP(751)SL mice
The number of microglia in both the cortex and hippocampus
of hAPP(751)SL mice with DM or apocynin treatment was counted
using CD11b immunoreactivity. Decreases in the number of
microglia in the cortex was observed in mice treated with 10 mg/
kg apocynin (p,0.05; Figure 2). No changes were seen in the
hippocampus (Table S1).
Neither dextromethorphan nor apocynin improve
behavioral deficits in hAPP(751)SL mice
Behavioral deficits were measured in hAPP(751)SL mice by
performance in the Morris Water Maze (MWM) through 3 daily
trials over 4 consecutive days after 4 months of treatment with
vehicle (0.9% saline), 15 mg/kg DM, 7.5 mg/kg DM, or 10 mg/kg
apocynin. Overall performance in the MWM was determined by
escape latency (seconds) and swimming path (meters). A downward
trend was observed within groups on subsequent days (data not
shown), indicating that each treatment group was able to learn and
improve overall performance. No significant changes were seen in
escape latency or swimming path between groups on any of the days
(Table S2). A trend in improvement in the swimming path was
observed between vehicle and apocynin treated mice on day 2 of the
4 day test (ANOVA p=0.084; t-test p= 0.024), although this was
not observed on any of the other days or other MWM tests. At the
end of the testing period (day 4), the hidden platform was removed
from the pool and measures of abidance in the target quadrant and
the number of target crossing were taken. No significant changes
were observed between groups for either measurement (Table S2).
Neither dextromethorphan nor apocynin alter synapse
density in the hippocampus of hAPP(751)SL mice
Synapse density was measured in the CA1, CA3, and GDmb
regions of the hippocampus with synaptophysin immunoreactivity.
Neither DM nor apocynin altered synapse density of any of the
regions examined (data not shown). This is consistent with the lack
of behavioral changes seen in hAPP(751)SL mice treated with
apocynin and DM.
NADPH oxidase activation, TNFa, lipid peroxidation, and
nitrotyrosine levels in hAPP(751)SL mouse brains are low,
and unaffected by treatment with dextromethorphan or
apocynin
The ability of DM and apocynin to reduce NADPH oxidase
activation in hAPP(751)SL mice was measured by western blot
analysis of translocation of the p67PHOX cytosolic protein to the
membrane, as previously reported [54]. Notably, there were low
levels of NADPH oxidase activation which was not modified by
either apocynin or DM (data not shown). Similarly the levels of
TNFa (as measured by ELISA) were not altered with DM or
apocynin treatment (data not shown), where levels of TNFa in
vehicle-treated controls were negligible (,100 pg/mg of total
protein), indicating low basal levels of TNFa in hAPP(751)SL mice
at 8 months of age. Levels of nitro-tyrosine were also measured via
ELISA, where again levels of nitrotyrosine in vehicle treated
controls (basal levels) were very low (1.32 mg/mL; Table S3),
further supporting an absence of oxidative stress.
Brain homogenates from each group (vehicle, 15 mg/kg DM,
7.5 mg/kg DM, 10 mg/kg apocynin) were used to measure the
levels of lipid peroxidation using a TBARS assay. Levels of
malondialdehyde (MDA) from each group were approximately
2.5 mM, suggesting low levels of oxidative stress. This is par-
ticularly interesting, as lipid peroxidation has previously been
reported to increase significantly in post-mortem analysis of
preclinical [55] and diagnosed AD [56,57] brain. No statistically
significant changes were observed in the levels between groups
(data not shown), indicating that the treatments (DM or apocynin)
to not alter levels of oxidative stress in hAPP(751)SL mice.
Thus, neuroinflammation and oxidative stress were not readily
apparent at 8 months of age in the hAPP(751)SL mice tested,
which may explain why the known NADPH oxidase inhibitors
failed to reduce these parameters. Together, these findings also
indicate that although apocynin inhibited microglial number and
plaque formation, it is very likely that it did so through
mechanisms that are independent of anti-inflammatory and
antioxidant properties. In addition, these findings also indicate
Figure 2. Apocynin reduces the number of microglia in the
cortex of hAPP(751)SL mice. Mice were treated daily with 15 mg/kg
dextromethorphan (DM), 7.5 mg/kg DM, or 10 mg/kg apocynin for four
months. The number of microglia was then counted for each group by
staining with anti-CD11b antibody and each treatment group was
compared to control. CD11b-stained microglia were only counted if they
corresponded to a DAPI stained nuclei (data not shown). Representative
images from each group of the stained microglia are shown in panel (A).
Apocynin reduced the number of microglia in the cortex of hAPP(751)SL
mice, whereas neither dose of DM reduced microglia number (B).
*p,0.05 vs vehicle, 1-way ANOVA with Bonferroni post-hoc test.
doi:10.1371/journal.pone.0020153.g002
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that Ab plaque load, microglia number, and learning deficits
may occur independently of neuroinflammation and oxidative
stress.
Apocynin & dextromethorphan reduce Ab-induced
superoxide and are neuroprotective in vitro
To confirm that both apocynin and DM were capable of
inhibiting NADPH oxidase at all, we next tested their ability to
reduce the production of extracellular ROS and neurotoxicity in
response to Ab. Both apocynin and DM were able to reduce the
production of Ab-induced extracellular superoxide to nearly
control levels in primary microglia cultures (Figure 3) and
ameliorate Ab-induced neurotoxicity in cortical mixed-neuron-
glia cultures (Figure 3). Thus, in the presence of microglial
NADPH oxidase activation in vitro, both compounds are able to
reduce extracellular ROS and cellular damage. These findings
further support that the inability of either DM or apocynin to
reduce measures of oxidative stress and synaptic density may have
been due to a lack of activation of NADPH oxidase and
neuroinflammation in hAPP(751)SL mice at 8 months.
Apocynin reduces H2O2, but does not reverse Ab-
induced decreases in phagocytosis in vitro
We confirmed that apocynin was working as predicted by
demonstrating that 30 minute pretreatment with apocynin will
attenuate LPS-induced H2O2 production (Figure 4). To test a
possible mechanism for the in vivo observation of decreased plaque
size with apocynin treatment, the capability of microglial to
phagocytize fluorescently labeled Ab was tested in microglial-
enriched primary cell cultures. Pre-treatment of cells with 2 mM
Ab for 24 hours prior to the addition of the fluorescent Ab
significantly reduces the phagocytosis capacity of microglia by
41% (p,0.05) (Figure 4). Co-treatment with 100 mM apocynin did
not reverse the Ab-induced decreases in fluorescent Ab phagocy-
tosis (Figure 4), supporting that superoxide and reactive oxygen
Figure 3. Apocynin reduces NADPH oxidase activation and is
neuroprotective in vitro. (A) Enriched microglia cultures were treated
with media alone (Control), apocynin (10 mM), Dextromethorphan (DM,
10 mM), Ab (2 mM), Apocynin + Ab, and DM + Ab. The production of
extracellular superoxide was measured by the superoxide dismutase
(SOD)-inhibitable reduction of tetrazolium salt, WST-1 at 30 minutes
post-treatment. Results are mean 6 SEM. Data are from four separate
experiments. *p,0.05, compared with control cultures. (B) Apocynin
and DM protect against Ab-induced toxicity in cortical neuron-glia
cultures.) Cortical neuron-glia cultures were treated with media alone
(Control), Apocynin (10 mM), Dextromethorphan (DM, 10 mM), Ab
(2 mM), Apocynin + Ab, and DM + Ab. Toxicity was assessed by MTT 7
days later. Graphs show the results expressed as percentage of the
control cultures and are the mean 6 SEM from three independent
experiments in triplicate. * p,0.05, control compared to treatment.
doi:10.1371/journal.pone.0020153.g003
Figure 4. Apocynin regulates microglial H2O2 production, but
not Ab phagocytosis. (A) Apocynin attenuates LPS-induced hydrogen
peroxide (H2O2), as predicted. Microglia-enriched cultures were treated
with Hank’s balanced salt solution (HBSS), or HBSS with LPS (10 ng/mL),
apocynin (100 mM), or the combination of apocynin (100 mM) and LPS
for 3 hours. The level of H2O2 was then measured in each group and
compared to control levels. Apocynin does significantly reduce LPS-
induced increases in H2O2, returning levels to control values. *p,0.05
vs. control; #p,0.05 vs. LPS, 1-way ANOVA with Bonferroni post-hoc
test. (B) Pre-treatment with 2 mM Ab significantly reduces phagocytosis
of fluorescent Ab, and apocynin does not act to reverse this decrease.
Microglia-enriched cultures were treated with control media, or media
with b-amyloid (Ab; 2 mM), apocynin (100 mM), or the combination of
apocynin (100 mM) and Ab (2 mM) for 24 hours. Fluorescently labeled
Ab (final concentration 0.1 mM) was then added to each well, and
incubated with the cells for 6 hours to allow for phagocytosis of the
fluorescent protein. The amount of phagocytosis of fluorescent Ab was
measured for each group and compared to control levels. *p,0.05 vs
control, 1-way ANOVA with Bonferroni post-hoc test.
doi:10.1371/journal.pone.0020153.g004
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species (e.g. ROS) do not mediate the Ab-induced loss of
phagocytic function. Thus, while loss of microglial phagocytic
function has been implicated as a key component to the
development of plaques and AD progression [58,59], apocynin
failed to ameliorate this response in vitro, indicating it is an
unlikely mechanism in the in vivo effects on plaque size.
Apocynin attenuates LPS-induced increases in cytokine
production in vitro
We then focused in vitro analyses specifically on apocynin, which
reduced both plaque size and microglial number in vivo. Specifically,
we next addressed whether apocynin was able to ameliorate a
generalized pro-inflammatory response from microglia. The pro-
inflammatory cytokine response of primary microglia-enriched
cultures was tested by measuring levels of TNFa following treatment
with 10 ng/mL LPS and/or 100 mM apocynin. LPS significantly
increased levels of TNFa at 24 hours after treatment (to 2907 pg/
mL), and apocynin was able to significantly reduce this response
(reduced to 1952 pg/mL), although levels did not return to that of
control (4 pg/mL) (Figure 5) (p,0.05). These data confirm that if
TNFa levels are elevated, in the very least, apocynin is able to
reduce them in vitro.
Apocynin does not inhibit apoptotic or inflammation-
induced cell death in microglia in vitro
We also considered that the reduction of microglial cell number
in the brains of hAPP(751)SL mice could be a result of increases
microglial cell death or a reduction in proliferation. To test
microglial cell survival in response to a number of toxic stimuli,
and the effect that apocynin has on this response, primary
microglia-enriched cultures were treated with 2 mM Ab, 1000 ng/
mL LPS (to cause inflammation-induced cell death), or 2 mM
staurosporine (to induce apoptotic cell death) in the presence and
absence of 100 mM apocynin. Neither Ab, apocynin, nor the
Figure 5. Apocynin ameliorates LPS-induced TNFa production, but has no effect on microglial cell death or cell number in vitro. (A)
Microglia-enriched cultures were treated with control media, lip polysaccharide (LPS; 10 ng/mL), and/or Apocynin (100 mM) for 24 hours. Tumor
necrosis factor alpha (TNFa) levels in the supernatant were measured via ELISA. LPS (10 ng/mL) significantly increased levels of TNFa and pre-
treatment with 100 mM Apocynin significantly reduced the amount of TNFa released by microglia. *p,0.05 vs. control; #p,0.05 vs. LPS, 1-way
ANOVA with Bonferroni post-hoc test. (B) Apocynin does not protect against inflammation-induced cell death. Microglia-enriched cultures were
treated with control media, 1000 ng/mL LPS, 100 mM Apocynin, or LPS and apocynin for 24 hours. After incubation, cell survival was measured with
the MTT assay. 100 ng/mL LPS significantly reduced microglial cell survival (through inflammation-induced cell death), which is not rescued by
apocynin). (C) Microglia-enriched cultures were treated with control media, 2 mM staurosporine (SS), 100 mM Apocynin, or SS and apocynin for
24 hours. After incubation, cell survival was measured with the MTT assay. Data show that 2 mM SS significantly reduces microglial cell survival
(through apoptosis), and is not reversed by the addition of apocynin. *p,0.05 vs control,1-way ANOVA with Bonferroni post-hoc test. (D) Apocynin
does not alter Ab or LPS-induced increases in microglia number in vitro. Mixed neuron-glia cultures were treated with 2 mM Ab, 10 ng/mL LPS and/or
100 mM apocynin for 24 hours. Cultures were then fixed and stained with IBA-1 antibody for microglia. The number of microglia was then counted in
9 representative areas per well. The number of microglia was significantly increased in cultures treated with LPS (196% of control) and Ab (186% of
control). Apocynin treatment did not prevent the increase in cell count caused by LPS or Ab. Apocynin alone caused no significant change in cell
count. *p,0.05 vs control, 1-way ANOVA with Bonferroni post-hoc test.
doi:10.1371/journal.pone.0020153.g005
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combination reduced cell survival in vitro (data not shown). Both
LPS (Figure 5) and staurosporine (Figure 5) significantly reduced
cell survival with 24 hours of treatment, but apocynin is not
capable of preventing either inflammation-induced or apoptotic
cell death (p,0.05) (Figure 5).
Apocynin does not alter Ab or LPS-induced increases in
microglia number in vitro
To look at the effect of Ab and/or apocynin on microglial cell
proliferation (to possibly account for the reduction in microglial
number observed in vivo), mixed neuron-glia cultures were treated
for 24 hours with 2 uM Ab, 10 ng/mL LPS and/or 100 mM
apocynin and microglia were stained with IBA-1 antibody, and
counted. Both LPS and Ab significantly increased the number of
microglia in the mixed neuron-glia culture (196% and 186% of
control, respectively; p,0.05) (Figure 5). Apocynin, however, had
no significant effect on the number of IBA-1 stained microglia in
LPS or Ab-treated mixed neuron-glia cultures.
Discussion
Accumulating evidence indicates that the ideal therapeutic
window for anti-inflammatory treatment targeting neurotoxic
microglial activation may be early in the neurodegenerative
process [26], highlighting a role for prevention. Microglial
NADPH oxidase has been implicated in the progressive nature
of AD through the chronic production of ROS in response to Ab
and/or neuron damage and the amplification of pro-inflammatory
factors, such as TNFa. Here, we used an in vivo/in vitro approach to
test the hypothesis that inhibition of NADPH oxidase reduces
microglia-mediated neuropathology (neuroinflammation, oxida-
tive stress, and neuron damage) and behavioral symptoms
(learning and memory deficits) associated with AD. Specifically,
using the hAPP(751)SL transgenic mouse model of AD, the
ability of chronic administration (4 month) of two NADPH
oxidase inhibitors (apocynin and DM) to prevent toxic microg-
lial activation, reduce plaque size, preserve neuron function, and
attenuate cumulative learning and memory deficits was tested.
Importantly, this study also addressed the utility of the hA-
PP(751)SL transgenic mouse model for testing anti-inflammatory
compounds. The hAPP(751)SL mice over-express human APP Swiss
and London mutations, with elevated expression in neurons
throughout the brain, pronounced expression in the hippocampus,
and little expression the periphery [60,61,62]. Amyloid depositions
occur as plaques and begin at 3 to 4 months in hAPP(751)SL mice,
with accumulation in the hippocampus commencing at 7 months
[60,61,62]. Using this defined window of plaque deposition, we
sought to prevent neuropathology and behavioral deficits by
administering the drugs early, from 4–8 months of age, before
significant damage had occurred. Despite the high level of Ab,
accumulation of Ab protein deposits, and behavioral deficits
associated with this model [60,61,62], we found that at 8 months
hAPP(751)SL mice showed little evidence of neuroinflammation and
oxidative stress in saline control animals, as TNFa protein, lipid
peroxidation, protein nitration, and NADPH oxidase activation
were low, making reduction by any inhibitors improbable. We were
intrigued by these findings, as there is a well established link between
Ab and neuroinflammation/oxidative stress [19]. Further, post-
mortem analysis of AD brains reveal microglia clustered around
plaques combined with high levels of oxidative stress and
neuroinflammation [63,64], including activation of NADPH oxidase
[1]. However, recent reports reveal distinct differences in murine AD
models when compared to the human disease that are consistent
with our findings. For example, the activation of complement, which
is absent in mouse models and present in human disease, has been
strongly implicated in the cross-species difference in neuroinflamma-
tion [65]. Yet, recent reports employing a slightly different murine
model, aged (14 month) R1.40 mice, show that NADPH oxidase is
activated in these aged mice and that this response can be modified
by ibuprophin [5]. While this study reported significant effects on
plaque load, microglial activation, and indicators of oxidative stress
that were modified by ibuprophin [5], the effect on cytokines, neuron
damage, and behavioral deficits were not discussed. Thus, it remains
possible that with significant aging (perhaps at 14 months) there
would be more pronounced evidence of NADPH oxidase activation
and neuroinflammation in the hAPP(751)SL model also.
However, despite the lack of evidence for NADPH oxidase-
induced pathology in vivo and the consequent inability of either
compound tested to regulate the enzyme complex’s low function in
hAPP(751)SL mice, apocynin (and not DM) treatment reduced
microglial number (Figure 2) and Ab plaque size (Figure 1) in vivo.
While in vitro analysis employed the use of immature cells and cell
lines, the data revealed that apocynin had no effect on microglia
cell death (Figure 5), nor microglial increases in neuron-glial
cultures treated with LPS or Ab (Figure 5). Together, these results
suggest that the reduction of microglia number in vivo may not be
due to direct effects of apocynin on microglial number, but may
instead occur through effects on the deposition, such as APP
processing/amyloidgenesis, Ab aggregation, Ab transport, or
degradation of Ab. Rather, we speculate that perhaps the
reduction in microglial number by apocynin may be driven by
the reduced plaque size.
The reduction in cortex and hippocampus plaque size conferred
by apocynin could be the consequence of a number of processes,
including plaque phagocytosis, deposition, degradation, or APP
processing and transport. As loss of microglial phagocytic function
has been implicated as a key component to the development of
plaques and AD progression [58,59], we next tested the ability of
apocynin to regulate Ab fibril phagocytosis. Our results indicate
that treatment of primary microglia cultures with high doses
(2 mM) of unlabeled, fibrilized Ab for 24 hours reduced the ability
of microglia to phagocytize fluorescent Ab after the unlabeled
ligand was washed away, supporting that high levels of Ab may
reduce microglial phagocytosis. However, our data also indicate
that apocynin does not modify Ab phagocytosis in any of the
conditions tested. Therefore, the reduction in plaque size observed
in hAPP(751)SL mice with apocynin treatment are independent
the microglial functions tested here.
Another interesting finding emphasized by this work is the
disconnect between plaque size and memory deficits in the
hAPP(751)SL mice. While apocynin was able to reduce plaque size
(Figure 1) and microglial number (Figure 2) in vivo, there were no
significant effects on behavior or synaptic density (synaptophysin
staining). This was unexpected, as apocynin has been shown to
protect against behavioral deficits linked to chronic brain hypoxia
[66] and presumably the behavior loss in hAPP(751)SL mice is due
to Ab deposition. As neuronal damage and behavioral deficits in
the hAPP(751)SL model peak around 14 months of age, aging may
again be necessary to acquire more AD-relevant pathology for this
model. Alternatively, it is also possible that a reduction of greater
than 50% of the plaque size is necessary to impact synaptic
plasticity and behavior.
The in vitro component of this study demonstrated that both
DM and apocynin attenuate Ab-induced extracellular superox-
ide (O2
N-) production in primary microglia cultures (Figure 3)
and protect against Ab-induced toxicity in cortical mixed
neuron-glia cultures (Figure 3), as expected. In addition, further
in vitro analysis with apocynin including several functional
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positive controls revealed that apocynin reduced H2O2 produc-
tion (Figure 4) and LPS-induced cytokine production (Figure 5),
demonstrating its established anti-inflammatory properties as
expected. Furthermore, apocynin and associated metabolites
readily reach the brain, where they have demonstrated
properties such as NADPH oxidase inhibition, neuroprotection,
and anti-inflammatory properties in other CNS disease models,
such as hypoxia [66]. This further supports the premise that
NADPH oxidase activation was not present in hAPP(751)SL
mice at this time.
In summary, apocynin treatment for 4 months in hAPP(751)SL
mice reduced plaque size and microglial number, resulting in
brains that resembled younger mice. In vitro analysis confirmed
that apocynin reduced Ab toxicity in mixed cortical neuron-glia
cultures, and H2O2, O2
N-, and TNFa production in primary
microglia cultures. However, in vivo analysis revealed no effects for
apocynin on synaptophysin (indicative of subleathal neuronal
damage) or behavioral measures of learning and memory. In fact,
upon further analysis, it was apparent that 8 month old
hAPP(751)SL mice presented low levels of neuroinflammation
and oxidative stress, which not surprisingly, was unaffected by
apocynin. Additional in vitro study indicated that apocynin failed to
affect microglial death, proliferation, and phagocytosis, indicating
that the microglia number and plaque size reduction in vivo likely
occur through unknown mechanisms that are independent of
apocynin’s anti-inflammatory characteristics. Together, these
findings suggest that apocynin is a unique NADPH oxidase
inhibitor with anti-b amyloid traits, supporting its possible use as a
novel and preventative therapeutic compound for early AD.
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Table S1 Microglial number in the hippocampus of
hAPP(751)SL mice. The number of microglia was measured in
hAPP(751)SL mice (Vehicle, DM 15 mg/kg, DM 7.5 mg/kg, and
Apocynin 10 mg/kg) following 4 months of treatment. While the
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(Figure 2), the number in the hippocampus showed only a trend
toward a decrease in the numbers, as seen by staining with anti-
CD11b antibody (statistical significance was tested with 1-way
ANOVA with Bonferroni post-hoc test).
(DOC)
Table S2 Behavioral measures in hAPP(751)SL mice.
hAPP(751)SL mice (Vehicle, DM 15 mg/kg, DM 7.5 mg/kg, and
Apocynin 10 mg/kg) were behaviorally tested using the Morris
Water Maze. Measures of time learning (escape latency), length
learning (length of swimming path), abidance in the target
quadrant (% of total time), and number of target crossings were
made for each animal, and values were compared to vehicle
treated animals and tested for statistical significance (1-way
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some tests. * p-value vs. vehicle is displayed when there was a
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Apocynin 10 mg/kg, total protein was isolated from the brains of
hAPP mice and the levels of nitrotyrosine were determined by
ELISA (Millipore). No significant changes were observed in the
levels of nitro-tyrosine between vehicle and treated mice.
However, it is of note that the levels are very low, even in the
vehicle treated hAPP transgenic mice (statistical significance was
tested with 1-way ANOVA).
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